HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight Chews On Strong Growth For Vitafusion As Consumers Stick To Category

Executive Summary

Vitafusion gummy vitamins had 24% consumption growth in Q3 and Zicam homeopathic cold remedies had 40%. Church & Dwight plans to increase prices on 80% of portfolio by the end of the 2022 Q1.

You may also be interested in...



US Q4 Consumer Health Earnings Preview: Inflation Impact Follows Pandemic-Driven Disruption

Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020.  More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.

C&D Expands Oral Care Portfolio, Acquires TheraBreath Mouthwash Brand In Latest Deal

Church & Dwight anticipates 15% growth for TheraBreath mouthwash brand in 2022 on larger sizes and wider distribution, especially outside US. It plans to acquire the firm for around $580m cash and close the deal before end of year

Church & Dwight Cuts Outlook Due To Rising Costs, Adds Suppliers To Strengthen ‘Weak Links’

“We expect higher input costs and transportation costs to remain elevated for the rest of the year,” says CEO Matthew Farrell. Firms lowers full-year outlook for net sales growth from previous range of 5% to 6% to around 5%.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS151903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel